CoChat

Generalized Cellular Hypertrophy is Induced by a Dual-Acting PPAR Agonist in Rat Urinary Bladder Urothelium In Vivo

Oleksiewicz, Martin B., Thorup, Inger, Nielsen, Henriette S., Andersen, Hanne V., Hegelund, Anne Charlotte, Iversen, Lars, Guldberg, Torben S., Brinck, Peter R., Sjogren, Ingrid, Thinggaard, Ulla K., Jørgensen, Lis, Jensen, Marianne B. · 2005 · Toxicologic Pathology
Cited by 44

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Some developmental dual-acting PPARα/γ agonists, such as ragaglitazar, have shown carcinogenic effects in the rodent urinary bladder urothelium after months-years of dosing. We examined early (precancerous) changes in the bladder urothelium of rats orally dosed with ragaglitazar, using a newly developed flow cytometric method. Following 3 weeks of oral ragaglitazar dosing, increases in physical size occurred in a generalized fashion in rat bladder urothelial cells, determined by flow cytometry. Protein/DNA measurements confirmed increased protein content of urothelial cells in the bladder, and hypertrophy was observed in the kidney pelvis urothelium by histopathology. In animals exhibiting urothelial hypertrophy, no cell cycle changes were detected in parallel samples of bladder urothelium. Interestingly, urothelial cells from normal rats were found to constitute a unique type of noncycling population, with high G2/M fractions. In summary, our findings showed that in the urothelium of ragaglitazar-treated animals, hypertrophy (increased size and protein content per cell) was an early change, that affected the whole bladder urothelial cell population. The urothelial hypertrophy was primary, i.e., occurred in the absence of similarly pronounced changes in cell cycle distributions. To our knowledge, this is the first report of a direct hypertrophic effect of a PPAR agonist. Urothelial hypertrophy might be a relevant early biological endpoint in mechanistic studies regarding the bladder-carcinogenic effect of PPAR agonists.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/01926230500214657

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Roles of PPARs in health and disease

    Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956 · cited 7×

    “In contrast, PPARβ/δ exhibits a more ubiquitous expression (Kersten et al., 2000; Abumrad, 2004; Michalik et al., 2004; Nahle, 2004).”
    BackgroundInfluential

Show all 1 references

Cited by

See all 44

Metadata

Authors
Oleksiewicz, M. B., Thorup, I., Nielsen, H. S., Andersen, H. V., Hegelund, A. C., Iversen, L., Guldberg, T. S., Brinck, P. R., Sjogren, I., Thinggaard, U. K., Jørgensen, L., & Jensen, M. B.
Venue
Toxicologic Pathology
Published
2005-08
Volume
33
Issue
5
Pages
552-560
ISSN
  • 0192-6233 (ISSN-L)
  • 1533-1601
OpenAlex
W2097170334
Cited by
44
References
1
FWCI
1.84
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Generalized Cellular Hypertrophy is Induced by a Dual-Acting PPAR Agonist in Rat Urinary Bladder Urothelium In Vivo. https://app.cochat.ai/papers/10.1080/01926230500214657
The paper
Oleksiewicz, M. B., Thorup, I., Nielsen, H. S., Andersen, H. V., Hegelund, A. C., Iversen, L., Guldberg, T. S., Brinck, P. R., Sjogren, I., Thinggaard, U. K., Jørgensen, L., & Jensen, M. B. (2005). Generalized Cellular Hypertrophy is Induced by a Dual-Acting PPAR Agonist in Rat Urinary Bladder Urothelium In Vivo. Toxicologic Pathology. https://doi.org/10.1080/01926230500214657

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.